Prognostic irrelevance of HLA-G in B-cell chronic lymphocytic leukemia

International Journal of Laboratory Hematology

Volumn 31, Issue 3, 2009, Pages 327-337

  Perez Chacon, G ^a   Rosado, S ^b   Rebolleda, N ^a   Losada Fernandez, I ^a   Vargas, J A ^b   Morado, M ^c   Jorda, J ^d   Perez Aciego, P ^a,e  

^a Fundacion LAIR   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e NONE   (Spain)

Author keywords

HLA G antigen; Prognostic marker

Indexed keywords

HLA G ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CANCER SURGERY; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HLA SYSTEM; HUMAN; HUMAN CELL; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROGNOSIS;

EID: 65349100500     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2008.01030.x     Document Type: Article

References (31)

1. Amiot L., Onno M., Renard I., Drenou B., Guillaudeux T., Le B.P. Fauchet R. (1996) HLA-G transcription studies during the different stages of normal and malignant hematopoiesis. Tissue Antigens 48, 609 614.
2. Amiot L., Onno M., Drenou B., Monvoisin C. Fauchet R. (1998) HLA-G class I gene expression in normal and malignant hematopoietic cells. Human Immunology 59, 524 528.
3. Amiot L., Le Friec G., Sebti Y., Drenou B., Pangault C., Guilloux V., Leleu X., Bernard M., Facon T. Fauchet R. (2003) HLA-G and lymphoproliferative disorders. Seminars in Cancer Biology 13, 379 385.
4. Chang C.C. Cleveland R.P. (2002) Conversion of CD38 and/or myeloid-associated marker expression status during the course of B-CLL: association with a change to an aggressive clinical course. Blood 100, 1106.
5. Chen L., Widhopf G., Huynh L., Rassenti L., Rai K.R., Weiss A. Kipps T.J. (2002) Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 100, 4609 4614.
6. Cheson B.D., Bennett J.M., Grever M., Kay N., Keating M.J., O'Brien S. Rai K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87, 4990 4997.
7. Chiorazzi N., Rai K.R. Ferrarini M. (2005) Chronic lymphocytic leukemia. The New England Journal of Medicine 352, 804 815.
8. Crisa L., McMaster M.T., Ishii J.K., Fisher S.J. Salomon D.R. (1997) Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. Journal of Experimental Medicine 186, 289 298.
9. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., Buchbinder A., Budman D., Dittmar K., Kolitz J., Lichtman S.M., Schulman P., Vinciguerra V.P., Rai K.R., Ferrarini M. Chiorazzi N. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94, 1840 1847.
10. Gibbs G., Bromidge T., Howe D., Hopkins J. Johnson S. (2005) Comparison of flow cytometric methods for the measurement of ZAP-70 expression in a routine diagnostic laboratory. Clinical and Laboratory Haematology 27, 258 266.
11. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G. Stevenson F.K. (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848 1854.
12. Hamblin T.J., Orchard J.A., Ibbotson R.E., Davis Z., Thomas P.W., Stevenson F.K. Oscier D.G. (2002) CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99, 1023 1029.
13. Hunt J.S., Petroff M.G., McIntire R.H. Ober C. (2005) HLA-G and immune tolerance in pregnancy. The FASEB Journal 19, 681 693.
14. Kansas G.S. Tedder T.F. (1991) Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. Journal of Immunology 147, 4094 4102.
15. Keating M.J., Chiorazzi N., Messmer B., Damle R.N., Allen S.L., Rai K.R., Ferrarini M. Kipps T.J. (2003) Biology and treatment of chronic lymphocytic leukemia. Hematology/American Society of Hematology Education Program, 153 175.
16. Kovats S., Main E.K., Librach C., Stubblebine M., Fisher S.J. DeMars R. (1990) A class I antigen, HLA-G, expressed in human trophoblasts. Science 248, 220 223.
17. Krober A., Seiler T., Benner A., Bullinger L., Bruckle E., Lichter P., Dohner H. Stilgenbauer S. (2002) V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100, 1410 1416.
18. Le D.M., Moreau P., Sabatier P., Legeais J.M. Carosella E.D. (2003) Expression of HLA-G in human cornea, an immune-privileged tissue. Human Immunology 64, 1039 1044.
19. LeMaoult J., Le Discorde M., Rouas-Freiss N., Moreau P., Menier C., McCluskey J. Carosella E.D. (2003) Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens 62, 273 284.
20. Mizuno S., Emi N., Kasai M., Ishitani A. Saito H. (2000) Aberrant expression of HLA-G antigen in interferon gamma-stimulated acute myelogenous leukaemia. British Journal of Haematology 111, 280 282.
21. Montillo M., Hamblin T., Hallek M., Montserrat E. Morra E. (2005) Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica 90, 391 399.
22. Nuckel H., Rebmann V., Durig J., Duhrsen U. Grosse-Wilde H. (2005) HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 105, 1694 1698.
23. Paul P., Cabestre F.A., Ibrahim E.C., Lefebvre S., Khalil-Daher I., Vazeux G., Quiles R.M., Bermond F., Dausset J. Carosella E.D. (2000) Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Human Immunology 61, 1138 1149.
24. Perez-Chacon G., Vargas J.A., Jorda J., Morado M., Rosado S., Martin-Donaire T., Losada-Fernandez I., Rebolleda N. Perez-Aciego P. (2007) CD5 provides viability signals to B cells from a subset of B-CLL patients by a mechanism that involves PKC. Leukemia Research 31, 183 193.
25. Polakova K., Krcova M., Kuba D. Russ G. (2003) Analysis of HLA-G expression in malignant hematopoetic cells from leukemia patients. Leukemia Research 27, 643 648.
26. Rosado S., Martin-Donaire T., Losada-Fernandez I., Perez-Aciego P., Jorda J. Vargas J.A. (2003) HLA-G expression in B-chronic lymphocytic leukaemia. Leukemia and Lymphoma 44, s20.
27. Rouas-Freiss N., Moreau P., Menier C. Carosella E.D. (2003) HLA-G in cancer: a way to turn off the immune system. Seminars in Cancer Biology 13, 325 336.
28. Sebti Y., Le Friec G., Pangault C., Gros F., Drenou B., Guilloux V., Bernard M., Lamy T., Fauchet R. Amiot L. (2003) Soluble HLA-G molecules are increased in lymphoproliferative disorders. Human Immunology 64, 1093 1101.
29. Shenkin M. Maiese R. (2006) Use of a blocking antibody method for the flow cytometric measurement of ZAP-70 in B-CLL. Cytometry Part B: Clinical Cytometry 70, 251 258.
30. Slack G.W., Wizniak J., Dabbagh L., Shi X., Gelebart P. Lai R. (2007) Flow cytometric detection of ZAP-70 in chronic lymphocytic leukemia: correlation with immunocytochemistry and Western blot analysis. Archives of Patholology and Laboratory Medicine 131, 50 56.
31. Smith S.H., Rigley K.P. Callard R.E. (1991) Activation of human B cells through the CD19 surface antigen results in homotypic adhesion by LFA-1-dependent and -independent mechanisms. Immunology 73, 293 297.